(Q39473961)

English

Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research

scientific article published on February 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research (English)

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

3

object named as

Tomasz M Beer

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

author name string

Julie N Graff

1

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Charles G Drake

2

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

language of work or name

0 references

publication date

1 February 2013

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

81

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

2

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

381-383

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4868050

12 September 2017

Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4868050

12 September 2017

Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4868050

12 September 2017

Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4868050

12 September 2017

Activation of thymic regeneration in mice and humans following androgen blockade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4868050

12 September 2017

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4868050

12 September 2017

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4868050

12 September 2017

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4868050

12 September 2017

T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4868050

12 September 2017

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4868050

17 June 2018

Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4868050

17 June 2018

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4868050

21 August 2018

Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4868050

21 August 2018

The evolution of antiandrogens: MDV3100 comes of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.10.044

7 January 2021

Identifiers

10.1016/J.UROLOGY.2012.10.044

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39473961&oldid=2186342932"